Your session is about to expire
← Back to Search
Supportive Care for Rectal Cancer (PATHWAYS Trial)
N/A
Recruiting
Led By Kelsey Lau-Min, MD, MSCE
Research Sponsored by Massachusetts General Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 weeks (study phase i only)
Awards & highlights
Summary
This trial studies how to help people with rectal cancer feel more confident before starting treatments.
Who is the study for?
This trial is for adults over 18 with newly diagnosed stage II or III locally advanced rectal cancer, who are starting combined treatments. Participants must be able to complete study tasks in English or with an interpreter's help.
What is being tested?
The trial tests a brief psychoeducational program called PATHWAYS against enhanced usual care to see if it can boost patients' confidence in managing their rectal cancer treatment and its effects.
What are the potential side effects?
Since the intervention is informational and supportive rather than medical, there may not be direct side effects like those from drugs; however, emotional distress or anxiety could potentially arise from discussing cancer-related topics.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 12 weeks (study phase i only)
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks (study phase i only)
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Proportion of participants retained in the intervention (feasibility)
Self-Efficacy (CASE-Cancer)
Secondary study objectives
Coping
Decisional Regret
Proportion of participants reporting acceptability of the intervention (acceptability)
+6 moreTrial Design
4Treatment groups
Experimental Treatment
Active Control
Group I: Study Phase II: PATHWAYS InterventionExperimental Treatment1 Intervention
Participants assigned to the PATHWAYS Intervention will receive: 1) four coaching sessions, 2) a comprehensive patient education guidebook, and 3) a coaching session workbook.
Group II: Study Phase I: PATHWAYS InterventionExperimental Treatment1 Intervention
Participants assigned to the PATHWAYS Intervention will receive: 1) four coaching sessions, 2) a comprehensive patient education guidebook, and 3) a coaching session workbook.
Group III: Study Phase I: Enhanced Usual CareActive Control1 Intervention
Participants assigned to the enhanced usual care will receive: 1) an information resource guide for navigating information online.
Group IV: Study Phase II: Enhanced Usual CareActive Control1 Intervention
Participants assigned to the enhanced usual care will receive: 1) an information resource guide for navigating information online.
Find a Location
Who is running the clinical trial?
Massachusetts General HospitalLead Sponsor
2,993 Previous Clinical Trials
13,230,601 Total Patients Enrolled
Kelsey Lau-Min, MD, MSCEPrincipal InvestigatorMassachusetts General Hospital
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have been treated for colorectal cancer before.I am 18 years old or older.I decided to undergo combined treatments for my stage II or III rectal cancer within the last 4 weeks.
Research Study Groups:
This trial has the following groups:- Group 1: Study Phase I: PATHWAYS Intervention
- Group 2: Study Phase I: Enhanced Usual Care
- Group 3: Study Phase II: PATHWAYS Intervention
- Group 4: Study Phase II: Enhanced Usual Care
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger